|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0020971,
umls-concept:C0021756,
umls-concept:C0033414,
umls-concept:C0034656,
umls-concept:C0042774,
umls-concept:C0150108,
umls-concept:C0205390,
umls-concept:C1318970,
umls-concept:C1412149,
umls-concept:C1511572,
umls-concept:C1963724,
umls-concept:C2587213
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-11-19
|
|
pubmed:abstractText |
Strategies to limit life-long dependence on antiretroviral therapy (ART) are needed. We randomized 81 human immunodeficiency virus (HIV)-infected subjects to 4 interventional arms involving continued ART plus ALVAC vCP1452 (or placebo) with or without interleukin (IL)-2 infusions. Viral load rebound 12 weeks after ART interruption was then analyzed to assess immune control. Fifty-two subjects reached the study end point. ALVAC recipients had 0.5 log(10) lower virologic rebounds (P=.033). IL-2 plus vaccine boosted CD4(+) T cell counts (P<.001) but did not diminish viral rebound. Significant changes were not detected for HIV-specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/AI 25859,
http://linkedlifedata.com/resource/pubmed/grant/AI 25868,
http://linkedlifedata.com/resource/pubmed/grant/AI 25915,
http://linkedlifedata.com/resource/pubmed/grant/AI 27658,
http://linkedlifedata.com/resource/pubmed/grant/AI 27660,
http://linkedlifedata.com/resource/pubmed/grant/AI 27661,
http://linkedlifedata.com/resource/pubmed/grant/AI 27663,
http://linkedlifedata.com/resource/pubmed/grant/AI 27666,
http://linkedlifedata.com/resource/pubmed/grant/AI 27673,
http://linkedlifedata.com/resource/pubmed/grant/AI 27675,
http://linkedlifedata.com/resource/pubmed/grant/AI 32770,
http://linkedlifedata.com/resource/pubmed/grant/AI 32775,
http://linkedlifedata.com/resource/pubmed/grant/AI 32782,
http://linkedlifedata.com/resource/pubmed/grant/AI 32783,
http://linkedlifedata.com/resource/pubmed/grant/AI 34832,
http://linkedlifedata.com/resource/pubmed/grant/AI 34853,
http://linkedlifedata.com/resource/pubmed/grant/AI 38855,
http://linkedlifedata.com/resource/pubmed/grant/AI 38858,
http://linkedlifedata.com/resource/pubmed/grant/AI 46339,
http://linkedlifedata.com/resource/pubmed/grant/AI 46370,
http://linkedlifedata.com/resource/pubmed/grant/M01 RR-00032
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:Adult AIDS Clinical Trials Group A5024 Protocol Team,
pubmed-author:AgaEvgeniaE,
pubmed-author:BoschRonald JRJ,
pubmed-author:BucyR PatRP,
pubmed-author:FischlMargaretM,
pubmed-author:FoxLawrenceL,
pubmed-author:HabibRaphaelle ElRE,
pubmed-author:KilbyJ MichaelJM,
pubmed-author:LawrenceJodyJ,
pubmed-author:LennoxJeffJ,
pubmed-author:MildvanDonnaD,
pubmed-author:MitsuyasuRonaldR,
pubmed-author:PilcherChrisC,
pubmed-author:PollardRichard BRB,
pubmed-author:SahnerDavidD,
pubmed-author:Santana-BagurJorgeJ,
pubmed-author:ZolopaAndrewA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
194
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1672-6
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17109338-AIDS Vaccines,
pubmed-meshheading:17109338-Adult,
pubmed-meshheading:17109338-Anti-HIV Agents,
pubmed-meshheading:17109338-Anti-Retroviral Agents,
pubmed-meshheading:17109338-CD4 Lymphocyte Count,
pubmed-meshheading:17109338-Drug Therapy, Combination,
pubmed-meshheading:17109338-Endpoint Determination,
pubmed-meshheading:17109338-HIV Infections,
pubmed-meshheading:17109338-HIV-1,
pubmed-meshheading:17109338-Humans,
pubmed-meshheading:17109338-Injections, Subcutaneous,
pubmed-meshheading:17109338-Interleukin-2,
pubmed-meshheading:17109338-RNA, Viral,
pubmed-meshheading:17109338-Recombinant Proteins,
pubmed-meshheading:17109338-Treatment Refusal,
pubmed-meshheading:17109338-Vaccination,
pubmed-meshheading:17109338-Viral Load
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
|
|
pubmed:affiliation |
University of Alabama at Birmingham, Birmingham, AL 35294-2050, USA. mkilby@uab.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
